Use of nontraditional animals for evaluation of pharmaceutical products

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 3, 2006, Pages 345-349

  Jacobs, Abigail ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Caenorhabditis elegans; Ferrets; Hamsters; Marmosets; Minipigs; Zebrafish

Indexed keywords

ANIMAL CARE; ANIMAL TESTING ALTERNATIVE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESEARCH; HAMSTER; INFECTION SENSITIVITY; MINIPIG; NONHUMAN; REVIEW; TOXICOLOGICAL PARAMETERS;

ANIMALS; CAENORHABDITIS ELEGANS; CALLITHRIX; CRICETINAE; DRUG EVALUATION, PRECLINICAL; FERRETS; MODELS, ANIMAL; SPECIES SPECIFICITY; SWINE; SWINE, MINIATURE; TOXICITY TESTS; ZEBRAFISH;

ANIMALIA; CAENORHABDITIS ELEGANS; CANIS FAMILIARIS; CRICETINAE; DANIO RERIO; MAMMALIA; MUSTELA; PRIMATES;

EID: 33846409886     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.3.345     Document Type: Review

References (43)

1. SVENDSEN O: Use of minipigs. The minipig in toxicology. Scand. J. Lab. Anim. Sci. (1998) 25(Suppl. 1).
2. SWINDLE MM, SMITH AC: Comparative physiology and anatomy of the pig. Scand. J. Lab. Anim. Sci. (1998) 25(Suppl. 1):11-22.
3. GAD SC: Pigs and ferrets as models in toxicology and biological safety assessment. Int. J. Toxicol. (2000) 19(3):149-168.
4. ELLEGAARD L, JØRGENSEN KD, KLASTRUP S, HANSEN AK, SVENDSEN O: Haematologic and clinical chemical values in 3 and 6 months old Göttingen minipigs. Scan. J. Lab. Anim. Sci. (1995) 3:239-248.
5. VAN VLEET JF, HERMAN EH, FERRANS VJ: Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine. Exp. Mol. Pathol. (1984) 41(1):10-25.
6. SKAANILD MT, FRIIS C: Expression changes of CYP2A and CYP3A in microsomes from pig liver and cultured hepatocytes. Pharm. Toxicol. (2000) 87:174-178.
7. SOUCEK P, ZUBER R, ANZENBACHEROVA E, ANZENBACHER P, GUENGERICH FP: Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol. (2001) 1:11.
8. ANZENBACHEROVA E, BARANOVA J, ZUBER R et al.: Model systems based on experimental animals for studies on drug metabolism in man: (mini) pig cytochromes P450 3A29 and 2E1. Basic Clin. Pharmacol. Toxicol. (2005) 96(3):244-245.
9. SKAANILD MT, FRIIS C: Is cytochrome P450 CYP2D activity present in pig liver? Pharmacol. Toxicol. (2002) 91(4):198-203.
10. ZUBER R, ANZENBACHEROVA E, ANZENBACHER P: Cytochromes P450 and experimental models of drug metabolism. J. Cell Mol. Med. (2002) 6(2):189-198.
11. SKAANILD MT, FRIIS C: Porcine CYP2A polymorphisms and activity. Basic Clin. Pharmacol Toxicol. (2005) 97(2):115-121.
12. DAMM JORGENSEN K: Minipig in reproduction toxicology. Scand. J. Lab. Anim. Sci. (1998) 25(Suppl. 1):63-75.
13. SVENDSEN O, KAABER K, HARLING RJ, MAKIN A GLERUP P: The minipig in toxicology and other non-clinical studies. Pharmacol. Toxicol. (2003) 93(Suppl. 1):25.
14. STANTON HC, MERSMANN HJ: Swine in Cardiovascular Research, Vol. 1 and 2. CRC Press, Boca Raton, FL, USA (1986).
15. PDR, Physicians Desk Reference. Medical Economics. Montvale, NJ, USA (2005).
16. MONTEIRO RIVIERE NA, RIVIERE J: The pig as a model for cutaneous pharmacology and toxicology research. In: Advances in Swine in Biomedical Research, Vol 2. ME Tumbleson, LB Schook (Eds), Plenum Press, NY, USA (1996):425-458.
17. NTP TR-246: Lifetime Carcinogenesis Studies of Chrysotile Asbestos (CAS No. 12001-29-5) in Syrian Golden Hamsters (Feed Studies) (1990).
18. MARSELOS M, TOMATIS L: Diethylstilboestrol: II, pharmacology, toxicology and carcinogenicity in experimental animals. Eur. J. Cancer (1992) 9A(1):149-155.
19. MORAND JP, MACRI J, ADELI K: Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia. J. Biol Chem. (2005) 280(18):17626-17633.
20. ZITZOW LA, ROWE T, MORKEN T, SHIEH W-J, ZAKI S, KATZ JK: Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virology (2002) 76:4420-4429.
21. LANGHEINRICH U, VACUN G, WAGNER T: Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. (2003) 193(3):370-382.
22. MILAN DJ, PETERSON TA, RUSKIN JN, PETERSON RT, MACRAE CA: Drugs that induce repolarization abnormalities cause bradycardia in Zebrafish. Circulation (2003) 107:1355-1358.
23. PARNG C, SEMINO C, MCGRATH P: Zebrafish: a preclinical model for drug screening. Assay Drug Dev. Technol. (2002) 1(1):41-48.
24. NAGEL R, DAR T: The embryo test with the Zebrafish Danio rerio - a general model in ecotoxicology and toxicology. ALTEX (2002) 19(Suppl. 1):38-48.
25. KIMMEL CB, BALLARD WW, KIMMEL SR, ULLMANN B, SCHILLING TF: Stages of embryonic development of the Zebrafish. Dev. Dyn. (1995) 203:253-310.
26. HAFFTER P, GRANATO M, BRAND M et al.: The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development (1996) 123:1-36.
27. INGHAM PW: Zebrafish genetics and its implications for understanding vertebrate development. Hum. Mol. Genet. (1997) 6:1755-1760.
28. COSTACHE AD, PULLELA PK, KASHA P, TOMASIEWICZ H, SEM DS: Homology-modeled ligand-binding domains of zebrafish estrogen receptors (α), (β) 1, and (β)2: from in silico to in vivo studies of estrogen interactions in Danio rerio as a model system. Mol. Endocrinol. (2005) 19:2979-2990.
29. GRUNWELLER A, HARTMANN RK: RNA interference as a gene-specific approach for molecular medicine. Curr. Med. Chem. (2005) 12(26):3143-3161.
30. ANDERSON G, COLE R, WILLIAMS P: Assessing behavioral toxicity using Caenorhabditis elegans. Environ. Toxicol. Chem. (2004) 23:1235-1240.
31. MEYERS SN, ROGATCHEVA MB, LARKIN DM et al.: Piggy-BACing the human genome II. A high-resolution, physically anchored, comparative map of the porcine autosomes. Genomics (2005) 86(6):739-752.
32. WERNERSSON R, SCHIERUP MH, JORGENSEN FG et al.: Pigs in sequence space: a 0.66X coverage pig genome survey based on shotgun sequencing. BMC Genomics (2005) 6(1):70.
33. ZHAO S-H, RECKNOR, J, LUNNEY JK et al.: Validation of a first-generation long-oligonucleotide microarray for transcriptional profiling in the pig. Genomics (2005) 6(5):618-625.
34. http://www.fda.gov/cder/guidance/index.htm ICH M3 International Conference on Harmonization: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (1997).
35. http://www.nal.usda.gov/awic/pubs/swine/sw ine.htm USDA Information Resources on Swine in Biomedical Research (1990-2000).
36. http://www.fda.gov/cder/guidance/index.htm USFDA CDER Guidance to Industry: Nonclinical Safety Evaluation of Pediatric Drug Products (2006).
37. http://www.fda.gov/cder/guidance/index.htm ICH S7A International Conference on Harmonization: Safety Pharmacology Studies for Human Pharmaceuticals (2001).
38. http://www.fda.gov/cder/guidance/index.htm ICH S7B International Conference on Harmonization: Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (2005).
39. http://www.fda.gov/cber/guidelines.htm USFDA CBER Guidance to Industry-considerations for plasmid DNA vaccines (2005).
40. http://www.fda.gov/cder/guidelines.htm USFDA CDER Guidance to Industry (draft) Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention (2005).
41. http://pin.primate.wisc.edu/callicam/research1.html PRIMATE INFONET: (2006).
42. http://ntp-server.niehs.nih.gov/fdes/06291.pdf NTP BOARD OF SCIENTIFIC COUNSELORS: Summary minutes (2004).
43. http://ntp.niehs.nih.gov/files/C_elegans_pres.pdf FREEDMAN JH NTP Research programme on Caenorhabditis elegans (2004).